3Z Pharmaceuticals
Incorporates the latest advances in disease modeling and behavioral genetics to discover novel drug candidates for CNS disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $2.0m | Seed |
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 57 % | 3 % | (72 %) | (68 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | 85 % | 105 % | 144 % | 322 % | 811 % | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (96 %) | 4 % | 46 % | (46 %) | (321 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 91 % | 175 % | 339 % | 812 % | 1914 % | - |
Source: Company filings or news article
Related Content
3Z Pharmaceuticals, Inc., established in 2021 by co-founders Adam Ezra and Christopher Vulpe, is a preclinical-stage biopharmaceutical company headquartered in Reykjavik, Iceland, with a research laboratory in the San Francisco Bay Area. The company operates at the intersection of advanced disease modeling, behavioral genetics, and artificial intelligence to accelerate the discovery of new drug candidates for central nervous system (CNS) disorders. This focus stems from the founders' backgrounds; Adam Ezra has experience in biotech business development, and Christopher Vulpe is a physician-scientist with expertise in genomics and toxicology, currently a professor at UCSF.
3Z's core business revolves around its proprietary drug discovery platform which utilizes high-throughput screening of whole organisms, specifically zebrafish larvae. This approach allows for the rapid assessment of a drug's effects on complex behaviors, aiming to identify compounds that can effectively treat psychiatric and neurological conditions like anxiety, depression, and schizophrenia. The company's methodology serves as an alternative to traditional target-based and cell-based screening, which often fail to predict a drug's ultimate success in treating complex brain disorders. By analyzing behavior, 3Z can screen vast libraries of compounds to find those with the most promising therapeutic potential early in the development process.
The company's business model is centered on leveraging its platform to discover and advance novel drug candidates through the preclinical stages. It then seeks to form strategic partnerships with larger pharmaceutical companies to conduct later-stage clinical trials and eventually bring these new therapies to market. In a significant milestone, 3Z Pharmaceuticals secured $3 million in a seed funding round in May 2024, co-led by Gultentang and BlueYard Capital, to further develop its platform and expand its drug discovery programs.
Keywords: CNS disorders, drug discovery, preclinical biopharma, zebrafish models, behavioral genetics, neuroscience, psychiatric therapeutics, high-throughput screening, pharmaceutical partnerships, neurological conditions